TTrialPathMatch Me to Trials
← Back to trials
RecruitingParkinson's DiseaseMajor Depressive Disorder

Imaging Depression in Parkinson's Disease

Eligible age

40–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

Sponsor: Yale University

You may qualify if…

  • ✓ 1. Age 40-80.
  • ✓ 2. For women of reproductive potential, a negative pregnancy test at screening and scanning
  • ✓ 3. For PD patients, clinical diagnosis of PD, able to consent and tolerate PET procedures
  • ✓ 4. For PD depression patients - at least moderate symptom severity as determined by at least 15 on the MADRS, which has shown maximum discrimination between depressed and non-depressed PD patients.
  • ✓ 5. For dPD patients undergoing ketamine, abstinence from drugs of abuse, other than alcohol, cannabis, nicotine and caffeine for the duration of the study. Patients with substance use disorders as defined by the DSM-5 will be excluded.

You may not qualify if…

  • ✕ 1. Dementia (Montreal Cognitive Assessment (MoCA) score \<21)
  • ✕ 2. A significant primary DSM-5 psychiatric disorder except for MDD
  • ✕ 3. A history of or current significant medical (e.g. cardiovascular, renal), or neurological (e.g. cerebrovascular, seizure, traumatic brain injury) illness other than PD that is unstable and significantly increase their risk and/or might affect the study objectives, as determined by study physicians.
  • ✕ 4. Prior radiation exposure for research purposes within such that participation in this study would place them over FDA limits for annual radiation exposure
  • ✕ 5. Medications affecting SV2A availability (e.g. levetiracetam)
  • ✕ 6. For dPD patients receiving ketamine, uncontrolled hypertension, defined as average blood pressure greater than or equal to 140 mmHg or an average diastolic blood pressure greater than or equal to 90 mmHg among those patients who have hypertension.
  • ✕ 7. Contraindications to MRI.
  • ✕ 8. For patients undergoing arterial sampling for the PET scan: Iodine allergy, bleeding disorder and/or use of blood thinning medication

Where it's recruiting

Connecticut

New Haven

Source: ClinicalTrials.gov · NCT06402955 · last updated 2026-03-10

Imaging Depression in Parkinson's Disease · TrialPath